MK-677 (Ibutamoren): The Oral Growth Hormone Secretagogue — Evidence, Dosing & Risks

Table of Contents

1. What Is MK-677?
2. Why MK-677 Is Not a Peptide — and Why It's Here
3. Mechanism of Action
4. Clinical Evidence
5. Dosing Protocols
6. Side Effects & Safety
7. The Insulin Resistance Question
8. Legal & Regulatory Status
9. MK-677 vs Injectable GH Peptides
10. Frequently Asked Questions
11. Sources

What Is MK-677?

MK-677, also known as Ibutamoren mesylate and previously designated L-163,191, is an orally active non-peptide agonist of the growth hormone secretagogue receptor (GHS-R1a) — the same receptor activated by the endogenous hormone ghrelin. It was developed by Merck & Co. in the 1990s as a potential treatment for growth hormone deficiency, muscle wasting, osteoporosis, and frailty in the elderly.¹

What sets MK-677 apart from every injectable GH peptide is its oral bioavailability. Peptides like Ipamorelin, GHRP-6, and Sermorelin are degraded by stomach acid and must be injected subcutaneously. MK-677 is a small molecule — not an amino acid chain — that survives gastrointestinal transit and is absorbed intact. A single daily capsule produces sustained GH pulsatility and IGF-1 elevation for approximately 24 hours.²

Despite promising early data, MK-677 has never received FDA approval. Its clinical development was effectively abandoned after Phase 2 trials in hip fracture recovery and Alzheimer's disease-related wasting failed to meet primary endpoints. It remains classified as an investigational new drug.³

Why MK-677 Is Not a Peptide — and Why It's Here

We should be transparent: MK-677 is not a peptide. It is a benzolactam derivative — a small organic molecule with a molecular weight of approximately 528 Da (versus 711 Da for the 5-amino-acid Ipamorelin). It contains no peptide bonds and is not synthesized from amino acids.

We include it in the Grey Peptides knowledge base because it operates within the same pharmacological space as peptide-based growth hormone secretagogues. It activates the identical receptor (GHS-R1a) as GHRP-6, GHRP-2, Ipamorelin, and Hexarelin. Users researching GH peptides will inevitably encounter MK-677 and need accurate, unbiased information about how it compares to injectable alternatives. Excluding it would leave an important gap in the reference.

Mechanism of Action

MK-677 is a full agonist of the GHS-R1a receptor, a G-protein-coupled receptor expressed in the hypothalamus and pituitary. When activated, this receptor stimulates growth hormone release through two complementary pathways: direct action on pituitary somatotroph cells and hypothalamic GHRH neurons, and suppression of somatostatin release (the hormone that inhibits GH secretion).¹

The result is amplified, pulsatile GH secretion that mimics the body's natural pattern — similar to what injectable GHRP peptides achieve. Key pharmacological properties include a plasma half-life of approximately 5–6 hours, a duration of biological effect of approximately 24 hours (due to receptor occupancy kinetics), no tachyphylaxis over at least 2 years of continuous dosing, and no suppression of endogenous GH production after cessation.²

Because MK-677 acts through the ghrelin receptor, it also produces ghrelin-like effects beyond GH release: increased appetite, potential effects on sleep architecture, and modest increases in cortisol and prolactin (though less pronounced than GHRP-6).⁴

Clinical Evidence

MK-677 has more published human clinical trial data than any other GH secretagogue. This is both its strength and its limitation — because the data ultimately showed the compound was not effective enough for FDA approval in its tested indications.

GH and IGF-1 elevation

Multiple studies have demonstrated that MK-677 at 25 mg/day produces consistent, dose-dependent increases in GH pulsatility and IGF-1 levels. In healthy young men, a single dose elevated 24-hour GH secretion by approximately 55% and IGF-1 by approximately 40%. In elderly subjects, similar doses restored IGF-1 levels to those of young adults.²

Two-year elderly study (Murphy et al.)

The landmark Murphy et al. study (2001) is the longest controlled trial of any GH secretagogue. Sixty-five healthy elderly adults received MK-677 25 mg or placebo daily for 2 years. The study found sustained IGF-1 elevation to the upper normal range of young adults, maintained throughout 2 years without tachyphylaxis. GH pulse amplitude increased significantly. Fat-free mass increased by approximately 1.6 kg versus placebo over 12 months, but this was not sustained at 24 months. There was no significant change in strength or physical function. Fasting glucose increased in the MK-677 group, raising insulin sensitivity concerns.³

Body composition and muscle

In a study of healthy obese males, MK-677 at 25 mg/day for 8 weeks increased fat-free mass by approximately 3 kg and basal metabolic rate. In food-restricted conditions, it reversed diet-induced nitrogen wasting (suggesting protein-sparing effects). However, these changes in lean mass have not consistently translated to functional improvements in strength or physical performance.⁵

Bone density

A 12-month study in postmenopausal women showed that MK-677 increased markers of bone turnover and bone mineral density at the femoral neck. This was one of the more promising clinical findings, suggesting potential utility in osteoporosis — but the study was not followed by pivotal Phase 3 trials.⁶

Failed indications

MK-677 failed to accelerate functional recovery in elderly patients with hip fractures (the primary endpoint was not met). It also failed to slow progression or improve outcomes in Alzheimer's disease trials. These failures, combined with safety concerns around glucose metabolism, effectively ended its commercial development trajectory.³

Dosing Protocols

Dosing information reflects published clinical data. This is not a recommendation. Always consult a licensed medical professional.

Clinical trial dosing

Virtually all published clinical trials used a dose of 25 mg once daily, taken orally with or without food. Some early dose-finding studies also evaluated 10 mg and 50 mg. The 25 mg dose consistently produced robust GH and IGF-1 elevation, while 10 mg produced a more modest but measurable response.²

Community protocols

In biohacker and research communities, dosing typically ranges from 10–25 mg daily. Some users start at 10 mg to assess tolerance (particularly appetite increase and water retention) before titrating to 25 mg. Administration is usually at bedtime to align with nocturnal GH secretion and minimize daytime hunger. Cycling patterns vary — common approaches include 12 weeks on / 4 weeks off, or 5 days on / 2 days off. These protocols are not clinically validated.

Side Effects & Safety

MK-677's side effect profile is well-documented from clinical trials involving hundreds of subjects.

Common effects

The most frequently reported side effects are increased appetite (a direct ghrelin-receptor effect, reported by 40–60% of subjects in some trials), water retention and edema (typically mild, manifesting as puffy face or swollen extremities in the first weeks), transient muscle pain and joint stiffness, and lethargy or drowsiness (some users report improved sleep; others experience daytime fatigue).³

Moderately concerning effects

MK-677 produces modest, dose-dependent increases in fasting blood glucose and HbA1c. It also mildly elevates cortisol and prolactin, though typically within the normal physiological range. Cortisol elevation peaks in the first weeks and tends to normalize with continued use. Prolactin elevations are less pronounced than with GHRP-6 but still measurable.⁴

Contraindications

MK-677 is contraindicated or requires extreme caution in individuals with active malignancy, uncontrolled diabetes or pre-diabetes (due to insulin sensitivity effects), congestive heart failure (edema risk), and active pituitary tumors. Periodic blood work — fasting glucose, HbA1c, IGF-1, cortisol, and prolactin — is strongly recommended during use.³

The Insulin Resistance Question

This deserves its own section because it is the single most important safety consideration with MK-677 and is frequently downplayed in community discussions.

Growth hormone is a counter-regulatory hormone to insulin. Sustained GH elevation — whether from exogenous HGH, MK-677, or any GH secretagogue — can reduce insulin sensitivity, increase hepatic glucose output, and elevate fasting blood glucose. This is a pharmacological reality, not a rare side effect.⁷

In the Murphy et al. 2-year study, the MK-677 group showed statistically significant increases in fasting glucose (approximately 5–10 mg/dL above placebo) and a trend toward higher HbA1c. Several subjects were discontinued from the study due to developing diabetes-range glucose levels. These were elderly subjects with age-related insulin sensitivity decline, which may represent a higher-risk population than young, insulin-sensitive users.³

The practical implication: anyone using MK-677 should monitor fasting glucose before starting, at 4–6 weeks, and periodically thereafter. Individuals with pre-existing insulin resistance, metabolic syndrome, PCOS, or family history of type 2 diabetes face elevated risk. Some community protocols attempt to mitigate this by cycling MK-677, co-administering berberine or metformin (with physician oversight), or limiting use to 8–12 week blocks. None of these mitigation strategies have been validated in controlled studies.

Legal & Regulatory Status

United States: MK-677 is not FDA-approved, not a controlled substance, and not available through compounding pharmacies. It is sold by research chemical vendors as "for research purposes only." The FDA has issued warning letters to companies marketing MK-677 as a dietary supplement, which it is not.⁸

International: Legal status varies. Australia's TGA classifies MK-677 as a Schedule 4 prescription-only medicine. China has banned its production and export. In the EU and UK, it occupies a gray area similar to other unapproved investigational drugs. WADA prohibits MK-677 under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics).

→ See Are Peptides Legal? for broader context.

MK-677 vs Injectable GH Peptides

MK-677 vs Ipamorelin

Both act on the ghrelin/GHS receptor but through different molecular mechanisms. Ipamorelin is highly selective for GH release with minimal cortisol and prolactin elevation. MK-677 is less selective, producing more appetite stimulation, more water retention, and more cortisol/prolactin elevation. Ipamorelin requires subcutaneous injection; MK-677 is oral. Ipamorelin's effect lasts approximately 2–3 hours per injection; MK-677's effect lasts approximately 24 hours.

MK-677 vs CJC-1295 + Ipamorelin stack

The CJC-1295 + Ipamorelin combination activates both the GHRH receptor and the GHS receptor for synergistic GH release. MK-677 only activates the GHS receptor. The stack is generally considered to produce a more physiological GH pulse with fewer metabolic side effects, but requires daily injections versus a single oral dose.

MK-677 vs Sermorelin

Sermorelin works through the GHRH receptor — an entirely different pathway from MK-677's ghrelin receptor. They are complementary, not interchangeable. Sermorelin has FDA-approval history and a longer clinical safety record. MK-677 has more published clinical trial data but has never been approved.

The trade-off

MK-677's advantage is convenience — no injections, no reconstitution, no refrigeration, once-daily dosing. Its disadvantages are less selectivity (more appetite, edema, cortisol), greater insulin sensitivity impact, and a less favorable regulatory status (research chemical vs. compounding pharmacy availability).

→ Compare side by side with the Peptide Comparison Tool.

Frequently Asked Questions

Related Tools & Guides

Related Articles

Sources

1. Patchett AA, Nargund RP, Tata JR, et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proceedings of the National Academy of Sciences. 1995;92(15):7001–7005. doi:10.1073/pnas.92.15.7001
2. Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)–insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology & Metabolism. 1996;81(12):4249–4257. doi:10.1210/jcem.81.12.8954023
3. Murphy MG, Plunkett LM, Gertz BJ, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. Journal of Clinical Endocrinology & Metabolism. 1998;83(2):320–325. doi:10.1210/jcem.83.2.4551. Also: Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Annals of Internal Medicine. 2008;149(9):601–611.
4. Copinschi G, Leproult R, Van Onderbergen A, et al. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997;66(4):278–286. doi:10.1159/000127249
5. Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. Journal of Clinical Endocrinology & Metabolism. 1998;83(2):362–369. doi:10.1210/jcem.83.2.4539
6. Murphy MG, Weiss S, McClung M, et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. Journal of Clinical Endocrinology & Metabolism. 2001;86(3):1116–1125. doi:10.1210/jcem.86.3.7294
7. Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews. 2009;30(2):152–177. doi:10.1210/er.2008-0027
8. FDA Warning Letters regarding MK-677 marketed as dietary supplements. Available via FDA Inspections, Compliance, Enforcement, and Criminal Investigations database.